Persistent symptoms in celiac disease and non-celiac gluten sensitivity (NCGS) can create uncertainty for clinicians and laboratory professionals, especially when standard investigations fail to clarify ongoing gluten exposure. Fecal Gluten Peptide testing directly detects gluten-derived peptides in stool after ingestion, providing clear evidence1. For gastroenterologists assessing gluten-free diet adherence and laboratories exploring objective testing solutions, this Q&A reviews how stool-based gluten peptide testing may support clinical evaluation, dietary counseling, and conversations about unintended exposure.
A: For patients with celiac disease or non-celiac gluten sensitivity (NCGS) who report strict adherence to a gluten-free diet but continue to experience symptoms, one of the most important clinical questions is whether ongoing gluten exposure may still be contributing. Stool-based gluten peptide testing offers a more direct way to assess whether recent ingestion may be part of the clinical picture.
A: Compared to urine-based testing, fecal gluten peptide testing offers a broader detection window, generally reflecting exposure over the prior 2–4 days rather than only several hours after ingestion. Stool testing is also less dependent on precise collection timing, hydration status, and renal clearance, which may make it a more practical way to assess intermittent or hidden gluten exposure.
A: Serology remains an important component of evaluation and follow-up, but it does not always capture recent or intermittent dietary exposure. Antibody-based markers reflect immune response, which may not align with short-term gluten ingestion. Fecal gluten peptide testing may provide complementary information by assessing whether gluten-derived peptides are present in stool, adding context when symptoms, serology, and patient-reported adherence do not fully explain the story.
A: Maintaining a strict gluten-free diet can be difficult, even for highly motivated patients. Hidden ingredients, cross-contact, restaurant meals, supplements, and mislabeled products can all lead to unintended exposure. Fecal Gluten Peptide testing may be a useful tool when clinicians want a more objective way to help assess whether recent gluten exposure could be contributing to persistent symptoms or limiting progress over time.
A: The Fecal Gluten Peptide test from Diagnostic Solutions Laboratory measures gluten immunogenic peptides (GIPs) in stool, including digestion-resistant fragments such as the 33-mer gliadin peptide. Because these peptides can pass through the gastrointestinal tract after gluten ingestion, their presence may help provide insight into recent exposure in a non-invasive way.
A: Fecal Gluten Peptide testing is intended to reflect recent exposure, generally within the prior 2–4 days, depending on the timing of ingestion and sample collection. This may make it particularly useful when clinicians are trying to determine whether gluten exposure occurred despite reported GFD adherence.
A: That is one of its most practical potential applications. Many patients who believe they are “doing everything right” may still be exposed through cross-contact or hidden sources. Objective evidence of recent exposure can help clinicians and patients determine whether unintentional gluten ingestion may still be contributing.
A: A negative fecal gluten peptide result can still be highly informative. If no gluten peptides are detected in stool, it may help shift the focus toward other possible contributors and guide more productive conversations around what to explore next.
A: Yes. Fecal Gluten Peptide testing may help support more productive conversations around adherence, food preparation, hidden sources of exposure, and next steps. In that way, it can be a useful adjunct to symptom review, dietary counseling, and broader clinical evaluation.
A: Immundiagnostik, Inc. provides the Gluten Fecal ELISA to labs in North America and is proud to partner with Diagnostics Solutions Laboratory and LabCorp. Both labs currently offer Fecal Gluten Peptide testing to support gastroenterologists assessing gluten-free diet adherence in celiac disease and NCGS
Monitoring adherence to a gluten-free diet is complex, particularly when symptoms persist. While no single test can answer every question, fecal gluten peptide testing may provide useful context by helping identify recent gluten ingestion in a non-invasive and objective way. For gastroenterologists, it can help support conversations around adherence and guide next steps. For laboratories, it represents an additional tool that may help clinicians better evaluate complex cases involving celiac disease or NCGS.
Discover more about Fecal Gluten Peptide testing by submitting the form below.
The Gluten Fecal ELISA is for research use only and is not for use in diagnostic procedures. The test is for lab professional use only. Gluten Peptide Testing is performed by Diagnostic Solutions Laboratory and LabCorp.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
